Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

32.70 -0.89 (-2.63%)

Streaming Delayed Price Updated: 3:51 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	1,392,316
Open	33.33
Bid (Size)	32.69 (400)
Ask (Size)	32.72 (400)
Prev. Close	33.59
Today's Range	32.58 - 34.21
52wk Range	25.81 - 50.00
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Performance

YTD	-20.5%	-20.5%
1 Month	-2.5%	-2.5%
3 Month	+11.7%	+11.7%
6 Month	-6.8%	-6.8%
1 Year	-30.6%	-30.6%

More News

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

November 04, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

November 04, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

October 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

October 28, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 24, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

September 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 19, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗

September 09, 2025

Via Benzinga

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

September 08, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts ↗

September 05, 2025

Via Benzinga

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 02, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx to Participate at Investor Conferences in September

August 29, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 29, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 25, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 21, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 21, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

August 18, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 17, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 13, 2025

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 32.70

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 11/24/25 03:51 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 2.32B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.